COYA News

ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)